Califf Confronts Opioids Challenge
This article was originally published in Scrip
Executive Summary
At his first report as commissioner to the FDA's Science Board on March 1, Robert Califf has decided to focus on the scourge of opioid addiction in the US and the challenges the agency is up against in that spotlight of approving new pain management medicines.